JP2019537624A5 - - Google Patents

Download PDF

Info

Publication number
JP2019537624A5
JP2019537624A5 JP2019542758A JP2019542758A JP2019537624A5 JP 2019537624 A5 JP2019537624 A5 JP 2019537624A5 JP 2019542758 A JP2019542758 A JP 2019542758A JP 2019542758 A JP2019542758 A JP 2019542758A JP 2019537624 A5 JP2019537624 A5 JP 2019537624A5
Authority
JP
Japan
Prior art keywords
compound
formula
benzimidazol
ethyl
methoxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019542758A
Other languages
English (en)
Japanese (ja)
Other versions
JP7194683B2 (ja
JP2019537624A (ja
Filing date
Publication date
Priority claimed from BR102016024814A external-priority patent/BR102016024814A2/pt
Application filed filed Critical
Publication of JP2019537624A publication Critical patent/JP2019537624A/ja
Publication of JP2019537624A5 publication Critical patent/JP2019537624A5/ja
Application granted granted Critical
Publication of JP7194683B2 publication Critical patent/JP7194683B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019542758A 2016-10-24 2017-10-23 化合物、化合物を得るための方法、医薬組成物、化合物の使用、ならびに精神医学的障害および/または睡眠障害を治療するための方法 Active JP7194683B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
BRBR1020160248140 2016-10-24
BR102016024814A BR102016024814A2 (pt) 2016-10-24 2016-10-24 composto, processo de obtenção do composto, composição farmacêutica, uso do composto e método de tratamento de desordens psiquiátricas e/ou distúrbios do sono
PCT/BR2017/050320 WO2018076090A1 (en) 2016-10-24 2017-10-23 Compounds, process for obtaining the compounds, pharmaceutical composition, use of the compounds and method for treating psychiatric disorders and/or sleep disorders

Publications (3)

Publication Number Publication Date
JP2019537624A JP2019537624A (ja) 2019-12-26
JP2019537624A5 true JP2019537624A5 (enExample) 2020-11-26
JP7194683B2 JP7194683B2 (ja) 2022-12-22

Family

ID=62023150

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019542758A Active JP7194683B2 (ja) 2016-10-24 2017-10-23 化合物、化合物を得るための方法、医薬組成物、化合物の使用、ならびに精神医学的障害および/または睡眠障害を治療するための方法

Country Status (20)

Country Link
US (2) US10781182B2 (enExample)
EP (2) EP3529234B1 (enExample)
JP (1) JP7194683B2 (enExample)
KR (1) KR102594251B1 (enExample)
CN (2) CN115181108A (enExample)
AR (1) AR109467A1 (enExample)
AU (1) AU2017351756B2 (enExample)
BR (1) BR102016024814A2 (enExample)
CL (1) CL2019001105A1 (enExample)
CO (1) CO2019004756A2 (enExample)
DK (1) DK3529234T3 (enExample)
EC (1) ECSP19032963A (enExample)
ES (2) ES2970546T3 (enExample)
FI (1) FI3529234T3 (enExample)
MX (1) MX392990B (enExample)
PE (2) PE20250558A1 (enExample)
PT (1) PT3529234T (enExample)
SG (2) SG11201903113TA (enExample)
UY (2) UY40644A (enExample)
WO (1) WO2018076090A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT3640251T (lt) 2016-10-24 2022-03-10 Astrazeneca Ab 6,7,8,9-tetrahidro-3h-pirazolo[4,3-f]izochinolino dariniai, tinkami vėžio gydymui
BR102016024814A2 (pt) * 2016-10-24 2018-05-08 Aché Laboratórios Farmacêuticos S.A. composto, processo de obtenção do composto, composição farmacêutica, uso do composto e método de tratamento de desordens psiquiátricas e/ou distúrbios do sono
MX2019008438A (es) 2017-01-30 2019-10-30 Astrazeneca Ab Moduladores del receptor de estrogeno.
AR121842A1 (es) * 2020-04-15 2022-07-13 Ache Laboratorios Farmaceuticos Sa Compuesto de benzimidazol para el tratamiento de trastornos metabólicos
IL297216A (en) 2020-04-24 2022-12-01 Astrazeneca Ab Dosage regimen for the treatment of cancer
JP7719796B2 (ja) 2020-04-24 2025-08-06 アストラゼネカ・アクチエボラーグ 医薬製剤

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2658818B1 (fr) 1990-02-27 1993-12-31 Adir Cie Nouveaux derives a structure naphtalenique, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
US5260051A (en) 1990-12-17 1993-11-09 Lever Brothers Company, Division Of Conopco, Inc. Compositions comprising phosphate ester compounds containing a beneficial reagent component
FR2674524B1 (fr) 1991-03-25 1993-05-21 Adir Nouveaux amides alkyl heterocycliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
FR2680366B1 (fr) 1991-08-13 1995-01-20 Adir Nouveaux derives d'arylethylamines, leurs procedes de preparation et les compositions pharmaceutiques qui les contiennent.
GB9326192D0 (en) 1993-12-22 1994-02-23 Glaxo Group Ltd Chemical compounds
US6376666B1 (en) * 1994-06-10 2002-04-23 Nauchno-Issledovatelsky Institut Farmakologii Rossiiskoi Akademii Meditsinskikh Nauk 2-mercaptobenzimidazole derivatives possessing pharmacological activity
US5496826A (en) 1994-09-02 1996-03-05 Bristol-Myers Squibb Company Pharmaceutical methods of using heterocyclic derivatives of N-phenylamides
FR2738818B1 (fr) 1995-09-18 1997-12-05 Valentonine Nouveaux derives d'oxydation d'indolylalkylamines, et leur utilisation a titre de medicament
US6034239A (en) 1996-03-08 2000-03-07 Takeda Chemical Industries, Ltd. Tricyclic compounds, their production and use
JP2884153B2 (ja) * 1996-03-08 1999-04-19 武田薬品工業株式会社 三環性化合物、その製造法および剤
ZA9711051B (en) 1996-12-10 1999-06-09 Bristol Myers Squibb Co Benzodioxole benzofuran dihydrobenzofuran and benzodioxane melatonergic agents
CA2334299A1 (en) 1998-06-05 1999-12-09 Pierre Dextraze Heterocyclic cis cyclopropane derivatives as melatonergic agents
EP1189900B1 (en) 1999-06-30 2004-01-14 Bristol-Myers Squibb Company Heterocyclic aminopyrrolidine derivatives as melatonergic agents
EP1467986A1 (en) * 2002-01-17 2004-10-20 Eli Lilly And Company Aza-cyclic compounds as modulators of acetylcholine receptors
JPWO2005080334A1 (ja) * 2004-02-23 2007-08-02 大日本住友製薬株式会社 新規ヘテロ環化合物
ES2264641B1 (es) * 2005-06-17 2008-03-01 Quimica Sintetica, S.A. Procedimiento para la obtencion de derivados de bencimidazol y sus intermedios.
WO2008032164A2 (en) * 2006-09-12 2008-03-20 Pfizer Products Inc. Benzimidazolone derivatives
WO2008051533A2 (en) * 2006-10-25 2008-05-02 Takeda Pharmaceutical Company Limited Benzimidazole compounds
RU2401831C2 (ru) * 2008-12-15 2010-10-20 Алла Хем, Ллс Средство, снижающее влечение к алкоголю, фармацевтическая композиция и способы ее получения, лекарственное средство и способ лечения
BR102016024814A2 (pt) * 2016-10-24 2018-05-08 Aché Laboratórios Farmacêuticos S.A. composto, processo de obtenção do composto, composição farmacêutica, uso do composto e método de tratamento de desordens psiquiátricas e/ou distúrbios do sono

Similar Documents

Publication Publication Date Title
JP2019537624A5 (enExample)
JP4742026B2 (ja) ロフルミラストの新規の製造方法
JP2012505872A5 (enExample)
JP2004506611A5 (enExample)
AR071267A1 (es) Procedimiento para la produccion de 2-(4-(2-fluorobenciloxi )bencilamino ( ralfinamida ) o 2-(4-(3-fluorobenciloxi )bencilamino ( safinamida ) con alto grado de pureza, uso de dichos compuestos para la preparacion de un medicamento y composiciones farmaceuticas de los mismos
JP2013139446A5 (enExample)
JP2015505301A5 (enExample)
JPWO2023099623A5 (enExample)
CN1849310A (zh) 作为大麻素受体调制剂的噻唑衍生物
CN1085659C (zh) 2-(4-取代)-苄基氨基-2-甲基-丙酰胺衍生物
JP2019519587A5 (enExample)
JP2017538689A5 (enExample)
JP2009537544A5 (enExample)
JP2012523440A5 (enExample)
JP2013521301A5 (enExample)
JP2015508092A5 (enExample)
CN101516835A (zh) 选择性雄激素受体调节剂、它们的类似物和衍生物以及它们的用途
JP2017508733A5 (enExample)
JP2010522710A5 (enExample)
FI3529234T3 (fi) Yhdiste, menetelmä yhdisteen saamiseksi, faramseuttinen koostumus, yhdisteiden käyttö ja menetelmä psykiatristen häiriöiden ja/tai unihäiriöiden hoitoon
RU2010113358A (ru) Гуанидинсодержащие соединения, применимые в качестве антагонистов мускариновых рецепторов
JP2008508247A5 (enExample)
CN115667236A (zh) 1,5-二氢-2,4-苯二氮䓬-3-酮衍生物及其应用
JP2017521364A5 (enExample)
JP2009040767A5 (enExample)